Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
FDA regulatory considerations for oncology drug development
FDA regulatory considerations for oncology drug development
Fuente:
Wiley Open Access
Saved in:
Bibliographic Details
Main Authors:
Hanlim Moon
,
Dae Young Zang
,
Min‐Hee Ryu
,
YeonSook Seo
,
Bitna Oh
,
Sunjin Hwang
,
Lee Farrand
Format:
Artículo Open Access
Published:
Wiley
2024
Subjects:
Pharmacology Research & Perspectives
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Internet
https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.1254
Similar Items
Expanding the use of real‐world data through the development of user‐friendly tools to support drug development: Example of an organ impairment dashboard
by: Bianca Vora, et al.
Published: (2024)
Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring
by: Ling Shu, et al.
Published: (2024)
Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia
by: Guangqing Xiao, et al.
Published: (2024)
HDAC4/5 Inhibitor, LMK‐235 Improves Animal Voluntary Movement in MPTP‐Induced Parkinson's Disease Model
by: Heejin Lee, et al.
Published: (2025)
Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience
by: Sandra Fontanals, et al.
Published: (2024)